FDA regulatory trends and risk management strategies for clinical development of drugs and devices.
Managing Clinical Risk for the Development of Drugs and Devices
Original price was: $400.00.$340.00Current price is: $340.00.
9999 in stock
9999 in stock
Description
This comprehensive analysis of FDA regulatory trends from 2020-2025 reveals clinical investigators face highest citation risk (72.9%) followed by IRBs (15.7%). The whitepaper addresses transformative regulatory developments including FDA’s September 2024 final guidance on Decentralized Clinical Trials (DCTs), January 2025 guidance on AI in regulatory decision-making, and October 2024 guidance on Electronic Systems in Clinical Investigations. Key sections cover DCT risk management, AI integration challenges including model credibility and bias monitoring, enhanced data integrity and cybersecurity requirements, and patient-focused drug development (PFDD) integration. It emphasizes emerging risk categories including Digital Health Technology Violations, Remote Monitoring Compliance Failures, AI Model Validation Deficiencies, and Cybersecurity Incident Management. The document provides actionable strategies for sponsors, investigators, and IRBs navigating the modern clinical trial landscape.
